BPTH BIO-PATH HOLDINGS, INC.

Price Chart

Executive Summary

Bio-Path Holdings issued Series S Preferred stock and warrants to its CEO's advisory firm, canceled a planned reverse split, and disclosed efforts to restructure operations and restart clinical trials. These actions consolidate control with management and signal a turnaround attempt amid financial distress.

Actionable Insight

Key Facts

• Issued 51 shares of Series S Preferred stock and 2 million warrants to Steel Giants Advisors LLC (controlled by CEO Vikram Grover), granting it 1% of diluted votes
• Used $10,000 in accrued payables as consideration for the issuance
• Canceled a previously approved 1-for-30 reverse stock split due to low outstanding shares
• Engaged Farrington Capital Group for $1,000 cash and 100,000 shares to enhance technological platforms
• Reserved 1.5 million stock options for a new Strategic Advisory Board
• In negotiations with creditors to restructure payables and potentially restart Phase 1/2 trials for AML, solid tumors, and obesity
• Filed to domesticate the corporation from Delaware to Wyoming

Financial Impact

$10,000 in payables converted to equity; 2.1 million new shares potentially issuable (2M via warrants, 51 via preferred conversion); 1.5M options reserved

Risk Factors

• Extreme shareholder dilution from warrant and option issuances
• Related-party transaction concerns with CEO-controlled entity receiving preferential terms
• Failure to restructure debt or restart trials could lead to continued operational decline
• OTC listing with low liquidity amplifies volatility risk

Market Snapshot

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

US Market Status